Log In
BCIQ
Print this Print this
 

TT-301 (oral)

  Manage Alerts
Collapse Summary General Information
Company Opko Health Inc.
DescriptionOral small molecule that inhibits the overproduction of inflammatory cytokines
Molecular Target Interleukin-1 (IL-1) beta ; Tumor necrosis factor (TNF) alpha
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$60.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/31/2016

$60.0M

0

0

Get a free BioCentury trial today